• Explore /
  • Poster
  • / Proton pump inhibitor use (PPI) in patients treated with immune checkpoint inhibitors (ICI) for advanced cancer: Survival and prior therapy.

Proton pump inhibitor use (PPI) in patients treated with immune checkpoint inhibitors (ICI) for advanced cancer: Survival and prior therapy.

Abstract Poster

Authors

null

Marium Husain

The Ohio State University Medical Center, Columbus, OH

Marium Husain , Menglin Xu , Sandipkumar Patel , Andrew Johns , Madison Grogan , Mingjia Li , Gabrielle Lopez , Abdul Miah , Rebecca Hoyd , YunZhou Liu , Mitchell Muniak , Tyler Haddad , Gabriel Tinoco , Kari Lynn Kendra , Gregory Alan Otterson , Carolyn J Presley , Daniel Spakowicz , Dwight Hall Owen

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2021 ASCO Annual Meeting

Session Type

Poster Session

Session Title

Developmental Therapeutics—Immunotherapy

Track

Developmental Therapeutics—Immunotherapy

Sub Track

Other Checkpoint Inhibitors (Non-PD1/PDL1, Monotherapy, or Combination)

Citation

J Clin Oncol 39, 2021 (suppl 15; abstr 2633)

DOI

10.1200/JCO.2021.39.15_suppl.2633

Abstract #

2633

Poster Bd #

Online Only

Abstract Disclosures

Similar Posters

Poster

2024 ASCO Gastrointestinal Cancers Symposium

Updated pooled analyses of first-line anti-PD1/PD-L1 inhibitors plus chemotherapy in advanced esophageal squamous cell carcinoma.

Updated pooled analyses of first-line anti-PD1/PD-L1 inhibitors plus chemotherapy in advanced esophageal squamous cell carcinoma.

First Author: Maysa Vilbert

First Author: Mario Machado Lopes

First Author: Xiaoting Ma

First Author: Lorenzo Pilla